What is Noble Financial’s Forecast for MariMed Q2 Earnings?

MariMed Inc. (OTCMKTS:MRMD) – Equities researchers at Noble Financial issued their Q2 2025 earnings per share (EPS) estimates for shares of MariMed in a research note issued on Monday, May 12th. Noble Financial analyst J. Gomes anticipates that the company will post earnings per share of ($0.01) for the quarter. Noble Financial currently has a “Strong-Buy” rating on the stock. Noble Financial also issued estimates for MariMed’s Q3 2025 earnings at ($0.01) EPS and Q4 2025 earnings at ($0.01) EPS.

MariMed Stock Performance

Shares of MRMD stock opened at $0.09 on Tuesday. The stock has a fifty day moving average price of $0.10 and a 200 day moving average price of $0.12. The stock has a market cap of $33.04 million, a PE ratio of -2.13 and a beta of 3.15. MariMed has a 1 year low of $0.07 and a 1 year high of $0.29. The company has a debt-to-equity ratio of 1.01, a quick ratio of 0.73 and a current ratio of 1.55.

MariMed (OTCMKTS:MRMD) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.01) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.01). The firm had revenue of $37.96 million during the quarter, compared to analysts’ expectations of $38.33 million. MariMed had a negative return on equity of 2.75% and a negative net margin of 10.97%.

MariMed Company Profile

MariMed Inc engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature’s Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby’s Baked brand; and drink mix under Vibations brand.